Mid-Atlantic Health Law TOPICS

For nearly three decades, the Department of Justice (DOJ) and Federal Trade Commission (FTC) provided clear guidance for competitor collaborations through a series of policy statements and guidelines. Among the most relied-upon were the 1996 Health Care Anti-trust Policy Statements and the 2000 Antitrust Guidelines for Collaborations Among Competitors.

These policies established “safety zones” that outlined when collaborations among competitors—such as joint purchasing, joint research, or marketing ventures—would not be challenged on antitrust grounds. The safety zones gave health systems and other market participants confidence that cooperative efforts designed to reduce costs or improve efficiency would not automatically attract enforcement scrutiny.

Withdrawal of the Guidelines

The stability and predictability offered by these safety zones have now come to an end. On December 11, 2024, the DOJ and FTC jointly withdrew the 2000 Guidelines, formally eliminating all antitrust safe harbors for competitor collaborations. The Agencies explained that the withdrawal was due to the Guidelines’ reliance on outdated analytical methods that failed to account for the realities of today’s markets, including advances in artificial intelligence (AI), algorithmic pricing, vertical integration, and roll-up strategies.

The decision followed the 2023 withdraw-al of the Health Care Antitrust Policy Statements, which had previously provided specific guidance for joint purchasing and information-sharing arrangements in the health care sector.

Future Implications

Moving forward, parties considering joint purchasing or similar collaborative ventures will need to document carefully the efficiencies and benefits of their arrangements, ensure that participation remains voluntary, and avoid coordination or information sharing beyond what is reasonably necessary for legitimate business purposes.

Blindly following the old safe harbors without more may not be enough to satisfy the FTC or the DOJ; however, adhering to the principles in those safe harbors may be a good starting point in the overall analysis. Companies should also anticipate increased regulatory attention to AI-driven pricing tools, data aggregation, and other emerging technologies that could facilitate coordinated conduct.

Tamia J. Morris
410-576-4021 • tmorris@gfrlaw.com